UPPSALA, Sweden, Jan. 27, 2022 /PRNewswire/ --
Ready to capitalize on a strong foundation
Q4 2021 highlights
Important events after the period
SEK m, unless otherwise stated | 2021 | 2020 | 2021 | 2020 |
Net revenues | 144.0 | 159.2 | 565.0 | 663.6 |
Cost of goods sold | -20.3 | -11.3 | -78.9 | -65.6 |
Operating expenses | -187.8 | -158.9 | -700.2 | -617.9 |
EBIT | -64.1 | -11.0 | -214.1 | -19.9 |
EBIT margin, % | -44.5% | -6.9% | -37.9% | -3.0% |
EBITDA | -48.5 | 1.0 | -161.0 | 19.0 |
Earnings per share, before dilution, SEK | -1.92 | -1.45 | -6.51 | -2.45 |
Earnings per share, after dilution, SEK | -1.92 | -1.45 | -6.51 | -2.45 |
Cash flow from operating activities | -80.6 | -11.2 | -229.0 | 16.8 |
Cash and cash equivalents | 504.1 | 505.3 | 504.1 | 505.3 |
Unless otherwise stated in this report, all data refers to the Group, and numbers relate to the current quarter while numbers in parentheses relate to the corresponding period in 2020.
Expanding the business
"I am pleased to report that the fourth quarter of 2021 saw a continued strong profit contribution from ZUBSOLV® and sales nearly in line with Q3. The financial contribution from ZUBSOLV® is important to maintain pace and enable us to continue building on the highlights of the quarter. During Q4 we showed a positive outcome for the OX124 pivotal trial, we informed about our new drug delivery platform amorphOXtm, and expanded our pipeline with a new pharmaceutical project OX640 (nasal epinephrine). Additionally, we initiated the launch of MODIAtm and after the end of the period, our partnership with Sober Grid reached a significant milestone establishing an agreement with Walgreens to make our collaborative services available on their Find Care® digital market place during the first quarter."
Full CEO Comments can be read in attached PDF
For further information, please contact
Nikolaj Sørensen, President and CEO, Joseph DeFeo, EVP and CFO, or Lena Wange, IR & Communications Director
Tel: +46 18 780 88 00, +1 855 982 7658, E-mail: [email protected]
Presentation
At 2 pm CET, the same day as the announcement of the report, Orexo invites analysts, investors and media to attend a presentation where Nikolaj Sørensen, CEO, Joseph DeFeo, CFO, and Robert Rönn, SVP and Head of R&D, will present the report and host a Q&A.
Questions can also be sent in advance to [email protected], no later than 11 am CET.
Please view the instructions below on how to participate.
Internet: https://tv.streamfabriken.com/orexo-q4-2021
Telephone: SE +46 8 50 55 83 74 UK +44 33 33 00 92 63 US +1 64 67 22 49 02
The presentation material will be available on Orexo´s website prior to the audiocast, view Investors/Reports, presentations.
This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 am CET on January 27, 2022.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/orexo/r/orexo-q4-2021--incl--full-year-report,c3493248
The following files are available for download:
Orexo Q4 2021, incl. Full Year Report_published January 27 2022 |
SOURCE Orexo
These press releases may also interest you
|